Both sorafenib and sulfasalazine are FDA approved drugs that have been shown to induce ferroptosis and inhibit tumor growth, however, in addition to inhibiting SLC7A11, sorafenib acts as a multi-kinase inhibitor and sulfasalazine blocks prostaglandin production (136, 137). The gene discussed is SLC7A11; the disease is neoplasm.